Exosomal miRNAs as Next-generation Therapy Vehicles in Breast Cancer

doi:10.2174/1566523223666230215103524
摘要

影响全世界女性生存的第二大普遍癌症是乳腺癌。乳腺癌治疗的最大挑战之一是癌细胞在一段时间后对各种药物产生化学耐药性。因此，早期乳腺癌诊断需要高度特异性的血液生物标志物，以克服化疗耐药性并提高患者的生存率。如今，外泌体miRNA作为早期诊断血液生物标志物因其高稳定性、由恶性肿瘤细胞分泌以及对不同乳腺癌亚型的优异特异性而备受关注。此外，外泌体 miRNA 通过与其靶基因的 3'UTR 结合并限制其产生来调节细胞增殖、侵袭、转移和凋亡。本综述重点关注外泌体 miRNA 通过靶向多种信号通路以及化疗敏感性和耐药机制在肿瘤发生中的功能。此外，本综述中讨论的越来越多的证据表明，循环外泌体 miRNA 可用作乳腺癌治疗的潜在下一代治疗靶标载体。
关键词: 外泌体miRNA，乳腺癌，治疗性生物标志物，转移，化学抗性，靶基因。
« Previous Next »
图形摘要

[1]
Thakur P, Saini RV, Chhillar AK, et al. Alteration in the expression of microRNA-21 regulated target genes: Role in breast cancer. Biocell  2022; 46(2): 309-24.
 [http://dx.doi.org/10.32604/biocell.2022.016916]

[2]
Wong GL, Abu Jalboush S, Lo HW. Exosomal MicroRNAs and organotropism in breast cancer metastasis. Cancers  2020; 12(7): 1827.
 [http://dx.doi.org/10.3390/cancers12071827] [PMID: 32646059]

[3]
Brody JG, Rudel R, Maxwell NI, Swedis SR. Mapping out a search for environmental causes of breast cancer. Public Health Rep  1996; 111(6): 494-507.
 [PMID: 8955694]

[4]
Steiner E, Klubert D, Knutson D. Assessing breast cancer risk in women. Am Fam Physician  2008; 78(12): 1361-6.
 [PMID: 19119554]

[5]
Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers  2019; 5(1): 66.
 [http://dx.doi.org/10.1038/s41572-019-0111-2] [PMID: 31548545]

[6]
Jaglan P, Dass R, Duhan M. Breast cancer detection techniques: issues and challenges. J Inst Eng Series B  2019; 100(4): 379-86.
 [http://dx.doi.org/10.1007/s40031-019-00391-2]

[7]
Hessvik NP, Llorente A. Current knowledge on exosome biogenesis and release. Cell Mol Life Sci  2018; 75(2): 193-208.
 [http://dx.doi.org/10.1007/s00018-017-2595-9] [PMID: 28733901]

[8]
Hurley JH. ESCRTs are everywhere. EMBO J  2015; 34(19): 2398-407.
 [http://dx.doi.org/10.15252/embj.201592484] [PMID: 26311197]

[9]
Zhang Y, Liu Y, Liu H, Tang WH. Exosomes: Biogenesis, biologic function and clinical potential. Cell Biosci  2019; 9(1): 19.
 [http://dx.doi.org/10.1186/s13578-019-0282-2] [PMID: 30815248]

[10]
Chiu YJ, Cai W, Shih YRV, Lian I, Lo YH. A single-cell assay for time lapse studies of exosome secretion and cell behaviors. Small  2016; 12(27): 3658-66.
 [http://dx.doi.org/10.1002/smll.201600725] [PMID: 27254278]

[11]
Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- 1. Haematologica  2011; 96(9): 1302-9.
 [http://dx.doi.org/10.3324/haematol.2010.039743] [PMID: 21606166]

[12]
Dabitao D, Margolick JB, Lopez J, Bream JH. Multiplex measurement of proinflammatory cytokines in human serum: Comparison of the meso scale discovery electrochemiluminescence assay and the cytometric bead array. J Immunol Methods  2011; 372(1-2): 71-7.
 [http://dx.doi.org/10.1016/j.jim.2011.06.033] [PMID: 21781970]

[13]
Najminejad H, Kalantar SM, Abdollahpour-Alitappeh M, et al. Emerging roles of exosomal miRNAs in breast cancer drug resistance. IUBMB Life  2019; 71(11): 1672-84.
 [http://dx.doi.org/10.1002/iub.2116] [PMID: 31322822]

[14]
Oliveto S, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. World J Biol Chem  2017; 8(1): 45-56.
 [http://dx.doi.org/10.4331/wjbc.v8.i1.45] [PMID: 28289518]

[15]
Bartel DP. MicroRNAs. Cell  2004; 116(2): 281-97.
 [http://dx.doi.org/10.1016/S0092-8674(04)00045-5] [PMID: 14744438]

[16]
Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun  2011; 2(1): 282.
 [http://dx.doi.org/10.1038/ncomms1285] [PMID: 21505438]

[17]
Kim J, Yao F, Xiao Z, Sun Y, Ma L. MicroRNAs and metastasis: Small RNAs play big roles. Cancer Metastasis Rev  2018; 37(1): 5-15.
 [http://dx.doi.org/10.1007/s10555-017-9712-y] [PMID: 29234933]

[18]
Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science  2001; 294(5543): 858-62.
 [http://dx.doi.org/10.1126/science.1065062] [PMID: 11679671]

[19]
Kobayashi T, Gu F, Gruenberg J. Lipids, lipid domains and lipid–protein interactions in endocytic membrane traffic. Semin Cell Dev Biol  1998; 9(5): 517-26.
 [http://dx.doi.org/10.1006/scdb.1998.0257] [PMID: 9835639]

[20]
Mathivanan S, Ji H, Simpson RJ. Exosomes: Extracellular organelles important in intercellular communication. J Proteomics  2010; 73(10): 1907-20.
 [http://dx.doi.org/10.1016/j.jprot.2010.06.006] [PMID: 20601276]

[21]
Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med  2010; 2(63)63ra94
 [http://dx.doi.org/10.1126/scitranslmed.3001375] [PMID: 21178137]

[22]
van Niel G, Porto-Carreiro I, Simoes S, Raposo G. Exosomes: A common pathway for a specialized function. J Biochem  2006; 140(1): 13-21.
 [http://dx.doi.org/10.1093/jb/mvj128] [PMID: 16877764]

[23]
Zhong S, Chen X, Wang D, et al. MicroRNA expression profiles of drug-resistance breast cancer cells and their exosomes. Oncotarget  2016; 7(15): 19601-9.
 [http://dx.doi.org/10.18632/oncotarget.7481] [PMID: 26910922]

[24]
Sueta A, Fujiki Y, Goto-Yamaguchi L, et al. Exosomal miRNA profiles of triple negative breast cancer in neoadjuvant treatment. Oncol Lett  2021; 22(6): 819.
 [http://dx.doi.org/10.3892/ol.2021.13080] [PMID: 34671433]

[25]
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology  2007; 133(2): 647-58.
 [http://dx.doi.org/10.1053/j.gastro.2007.05.022] [PMID: 17681183]

[26]
Silver FH. Mechanotransduction-The relationship between gravity, cells and tensile loading in extracellular matrix. Biocell  2022; 46(2): 297.
 [http://dx.doi.org/10.32604/biocell.2022.017406]

[27]
Santos JC, Lima NS, Sarian LO, Matheu A, Ribeiro ML, Derchain SFM. Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep  2018; 8(1): 829.
 [http://dx.doi.org/10.1038/s41598-018-19339-5] [PMID: 29339789]

[28]
Sharma Y, Saini AK, Kashyap S, et al. Host miRNA and immune cell interactions: Relevance in nano-therapeutics for human health. Immunol Res  2022; 70(1): 1-18.
 [http://dx.doi.org/10.1007/s12026-021-09247-8] [PMID: 34716546]

[29]
Montecalvo A, Larregina AT, Shufesky WJ, et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood  2012; 119(3): 756-66.
 [http://dx.doi.org/10.1182/blood-2011-02-338004] [PMID: 22031862]

[30]
Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol  2013; 200(4): 373-83.
 [http://dx.doi.org/10.1083/jcb.201211138] [PMID: 23420871]

[31]
Mentkowski KI, Snitzer JD, Rusnak S, Lang JK. Therapeutic potential of engineered extracellular vesicles. AAPS J  2018; 20(3): 50.
 [http://dx.doi.org/10.1208/s12248-018-0211-z] [PMID: 29546642]

[32]
Rana S, Yue S, Stadel D, Zöller M. Toward tailored exosomes: The exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol  2012; 44(9): 1574-84.
 [http://dx.doi.org/10.1016/j.biocel.2012.06.018] [PMID: 22728313]

[33]
Vallee RB, Herskovits JS, Aghajanian JG, Burgess CC, Shpetner HS. Dynamin, a GTPase involved in the initial stages of endocytosis. Ciba Found Symp  1993; 176: 185-93.
 [PMID: 8299419]

[34]
Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol  2019; 21(1): 9-17.
 [http://dx.doi.org/10.1038/s41556-018-0250-9] [PMID: 30602770]

[35]
He J, Ren W, Wang W, Han W, Jiang L, Zhang D, et al. Exosomal targeting and its potential clinical application. Drug Deliv Transl Res  2021; 6: 1-8.
 [PMID: 34973131]

[36]
Zhang J, Li S, Li L, et al. Exosome and exosomal microRNA: Trafficking, sorting, and function. Genomics Proteomics Bioinformatics  2015; 13(1): 17-24.
 [http://dx.doi.org/10.1016/j.gpb.2015.02.001] [PMID: 25724326]

[37]
He Y, Deng F, Yang S, et al. Exosomal microRNA: A novel biomarker for breast cancer. Biomarkers Med  2018; 12(2): 177-88.
 [http://dx.doi.org/10.2217/bmm-2017-0305] [PMID: 29151358]

[38]
Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res  2011; 13(6): 227.
 [http://dx.doi.org/10.1186/bcr2912] [PMID: 22078026]

[39]
Liu Q, Peng F, Chen J. The role of exosomal microRNAs in the tumor microenvironment of breast cancer. Int J Mol Sci  2019; 20(16): 3884.
 [http://dx.doi.org/10.3390/ijms20163884] [PMID: 31395836]

[40]
Soysal SD, Tzankov A, Muenst SE. Role of the tumor microenvironment in breast cancer. Pathobiology  2015; 82(3-4): 142-52.
 [http://dx.doi.org/10.1159/000430499] [PMID: 26330355]

[41]
Li JJ, Tsang JY, Tse GM. Tumor microenvironment in breast cancer—updates on therapeutic implications and pathologic assessment. Cancers  2021; 13(16): 4233.
 [http://dx.doi.org/10.3390/cancers13164233] [PMID: 34439387]

[42]
Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol  2015; 26(2): 259-71.
 [http://dx.doi.org/10.1093/annonc/mdu450] [PMID: 25214542]

[43]
Choi WWL, Lewis MM, Lawson D, et al. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol  2005; 18(1): 143-52.
 [http://dx.doi.org/10.1038/modpathol.3800253] [PMID: 15297858]

[44]
Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes Dev  2016; 30(9): 1002-19.
 [http://dx.doi.org/10.1101/gad.279737.116] [PMID: 27151975]

[45]
Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell  2005; 121(3): 335-48.
 [http://dx.doi.org/10.1016/j.cell.2005.02.034] [PMID: 15882617]

[46]
Swartz MA, Iida N, Roberts EW, et al. Tumor microenvironment complexity: Emerging roles in cancer therapy. Cancer Res  2012; 72(10): 2473-80.
 [http://dx.doi.org/10.1158/0008-5472.CAN-12-0122] [PMID: 22414581]

[47]
Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev  2013; 32(1-2): 303-15.
 [http://dx.doi.org/10.1007/s10555-012-9415-3] [PMID: 23114846]

[48]
Yan W, Wu X, Zhou W, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol  2018; 20(5): 597-609.
 [http://dx.doi.org/10.1038/s41556-018-0083-6] [PMID: 29662176]

[49]
Fong MY, Zhou W, Liu L, et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol  2015; 17(2): 183-94.
 [http://dx.doi.org/10.1038/ncb3094] [PMID: 25621950]

[50]
Baroni S, Romero-Cordoba S, Plantamura I, et al. Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis  2016; 7(7)e2312
 [http://dx.doi.org/10.1038/cddis.2016.224] [PMID: 27468688]

[51]
Gupta GP, Massagué J. Cancer metastasis: Building a framework. Cell  2006; 127(4): 679-95.
 [http://dx.doi.org/10.1016/j.cell.2006.11.001] [PMID: 17110329]

[52]
Thulin A, Rönnerman E, Zhang C, et al. Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years. Breast  2020; 50: 113-24.
 [http://dx.doi.org/10.1016/j.breast.2020.02.007] [PMID: 32145571]

[53]
Suh JH, Kotecha R, Chao ST, Ahluwalia MS, Sahgal A, Chang EL. Current approaches to the management of brain metastases. Nat Rev Clin Oncol  2020; 17(5): 279-99.
 [http://dx.doi.org/10.1038/s41571-019-0320-3] [PMID: 32080373]

[54]
Singh R, Pochampally R, Watabe K, Lu Z, Mo YY. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer  2014; 13(1): 256.
 [http://dx.doi.org/10.1186/1476-4598-13-256] [PMID: 25428807]

[55]
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature  2007; 449(7163): 682-8.
 [http://dx.doi.org/10.1038/nature06174] [PMID: 17898713]

[56]
Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem  2003; 278(7): 5277-84.
 [http://dx.doi.org/10.1074/jbc.M210063200] [PMID: 12446667]

[57]
Zhou W, Fong MY, Min Y, et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell  2014; 25(4): 501-15.
 [http://dx.doi.org/10.1016/j.ccr.2014.03.007] [PMID: 24735924]

[58]
Tominaga N, Kosaka N, Ono M, et al. Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood–brain barrier. Nat Commun  2015; 6(1): 6716.
 [http://dx.doi.org/10.1038/ncomms7716] [PMID: 25828099]

[59]
Zhang L, Zhang S, Yao J, et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature  2015; 527(7576): 100-4.
 [http://dx.doi.org/10.1038/nature15376] [PMID: 26479035]

[60]
Xing F, Liu Y, Wu SY, et al. Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res  2018; 78(15): 4316-30.
 [http://dx.doi.org/10.1158/0008-5472.CAN-18-1102] [PMID: 30026327]

[61]
Le MTN, Hamar P, Guo C, et al. miR-200–containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest  2014; 124(12): 5109-28.
 [http://dx.doi.org/10.1172/JCI75695] [PMID: 25401471]

[62]
Lim PK, Bliss SA, Patel SA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res  2011; 71(5): 1550-60.
 [http://dx.doi.org/10.1158/0008-5472.CAN-10-2372] [PMID: 21343399]

[63]
Ono M, Kosaka N, Tominaga N, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal  2014; 7(332): ra63.
 [http://dx.doi.org/10.1126/scisignal.2005231] [PMID: 24985346]

[64]
Wu HJ, Hao M, Yeo SK, Guan JL. FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication. Oncogene  2020; 39(12): 2539-49.
 [http://dx.doi.org/10.1038/s41388-020-1162-2] [PMID: 31988451]

[65]
Ozawa PMM, Alkhilaiwi F, Cavalli IJ, Malheiros D, de Souza FREM, Cavalli LR. Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat  2018; 172(3): 713-23.
 [http://dx.doi.org/10.1007/s10549-018-4925-5] [PMID: 30173296]

[66]
Li C, Zhou T, Chen J, et al. The role of Exosomal miRNAs in cancer. J Transl Med  2022; 20(1): 6.
 [http://dx.doi.org/10.1186/s12967-021-03215-4] [PMID: 34980158]

[67]
Rodríguez-Martínez A, de Miguel-Pérez D, Ortega FG, et al. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. Breast Cancer Res  2019; 21(1): 21.
 [http://dx.doi.org/10.1186/s13058-019-1109-0] [PMID: 30728048]

[68]
Wang B, Zhang Y, Ye M, Wu J, Ma L, Chen H. Cisplatin-resistant MDA-MB-231 cell-derived exosomes increase the resistance of recipient cells in an exosomal miR-423-5p-dependent manner. Curr Drug Metab  2019; 20(10): 804-14.
 [http://dx.doi.org/10.2174/1389200220666190819151946] [PMID: 31424364]

[69]
Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II. Therapy resistance mediated by exosomes. Mol Cancer  2019; 18(1): 58.
 [http://dx.doi.org/10.1186/s12943-019-0970-x] [PMID: 30925921]

[70]
Guan J, Chen J. Mesenchymal stem cells in the tumor microenvironment. Biomed Rep  2013; 1(4): 517-21.
 [http://dx.doi.org/10.3892/br.2013.103] [PMID: 24648978]

[71]
Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol  2012; 227(2): 658-67.
 [http://dx.doi.org/10.1002/jcp.22773] [PMID: 21465472]

[72]
Hu J, Kwak KJ, Shi J, Yu B, Sheng Y, Lee LJ. Overhang molecular beacons encapsulated in tethered cationic lipoplex nanoparticles for detection of single-point mutation in extracellular vesicle-associated RNAs. Biomaterials  2018; 183: 20-9.
 [http://dx.doi.org/10.1016/j.biomaterials.2018.08.038] [PMID: 30145409]

[73]
Pan X, Hong X, Lai J, et al. Exosomal MicroRNA-221-3p confers adriamycin resistance in breast cancer cells by targeting PIK3R1. Front Oncol  2020; 10: 441.
 [http://dx.doi.org/10.3389/fonc.2020.00441] [PMID: 32426266]

[74]
Yamamoto Y, Yoshioka Y, Minoura K, et al. An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol Cancer  2011; 10(1): 135.
 [http://dx.doi.org/10.1186/1476-4598-10-135] [PMID: 22051041]

[75]
Zhu Y, Wu J, Li S, et al. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells. Cell Physiol Biochem  2013; 32(5): 1225-37.
 [http://dx.doi.org/10.1159/000354521] [PMID: 24335172]

[76]
Wang Z, Wang N, Liu P, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget  2014; 5(16): 7013-26.
 [http://dx.doi.org/10.18632/oncotarget.2192] [PMID: 25026296]

[77]
Cataldo A, Cheung DG, Balsari A, et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget  2016; 7(1): 786-97.
 [http://dx.doi.org/10.18632/oncotarget.6381] [PMID: 26623722]

[78]
Sprowl JA, Parissenti A. Abstract 3550: Role of TNFα in the cytotoxicity of docetaxel and in docetaxel resistance in MCF-7 cells. Cancer Res  2010; 70(8) (Supplement): 3550.
 [http://dx.doi.org/10.1158/1538-7445.AM10-3550]

[79]
Chen W, Liu X, Lv M, et al. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs. PLoS One  2014; 9(4)e95240
 [http://dx.doi.org/10.1371/journal.pone.0095240] [PMID: 24740415]

[80]
Chen W, Xu L, Qian Q, et al. d Rhamnose β-hederin reverses chemoresistance of breast cancer cells by regulating exosome-mediated resistance transmission. Biosci Rep  2018; 38(5)BSR20180110
 [http://dx.doi.org/10.1042/BSR20180110] [PMID: 30061173]

[81]
Zhao Y, Jin LJ, Zhang XY. Exosomal miRNA-205 promotes breast cancer chemoresistance and tumorigenesis through E2F1. Aging  2021; 13(14): 18498-514.
 [http://dx.doi.org/10.18632/aging.203298] [PMID: 34292880]

[82]
Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat  2014; 147(2): 423-31.
 [http://dx.doi.org/10.1007/s10549-014-3037-0] [PMID: 25007959]

[83]
Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther  2001; 1(2): 85-94.
 [PMID: 12467226]

[84]
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med  2001; 344(11): 783-92.
 [http://dx.doi.org/10.1056/NEJM200103153441101] [PMID: 11248153]

[85]
Gong C, Yao Y, Wang Y, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem  2011; 286(21): 19127-37.
 [http://dx.doi.org/10.1074/jbc.M110.216887] [PMID: 21471222]

[86]
Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell  2004; 6(2): 117-27.
 [http://dx.doi.org/10.1016/j.ccr.2004.06.022] [PMID: 15324695]

[87]
De Mattos-Arruda L, Bottai G, Nuciforo PG, et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget  2015; 6(35): 37269-80.
 [http://dx.doi.org/10.18632/oncotarget.5495] [PMID: 26452030]

[88]
Ye X, Bai W, Zhu H, et al. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Rep  2014; 47(5): 268-73.
 [http://dx.doi.org/10.5483/BMBRep.2014.47.5.165] [PMID: 24286315]

[89]
Ye XM, Zhu HY, Bai WD, et al. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer  2014; 14(1): 134.
 [http://dx.doi.org/10.1186/1471-2407-14-134] [PMID: 24571711]

[90]
Venturutti L, Cordo RRI, Rivas MA, et al. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene  2016; 35(48): 6189-202.
 [http://dx.doi.org/10.1038/onc.2016.151] [PMID: 27157613]

[91]
Ma T, Yang L, Zhang J. MiRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation. Oncol Rep  2015; 33(3): 1215-20.
 [http://dx.doi.org/10.3892/or.2015.3713] [PMID: 25586125]

[92]
Kim VN. MicroRNA biogenesis: Coordinated cropping and dicing. Nat Rev Mol Cell Biol  2005; 6(5): 376-85.
 [http://dx.doi.org/10.1038/nrm1644] [PMID: 15852042]

[93]
Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res  2011; 39(16): 7223-33.
 [http://dx.doi.org/10.1093/nar/gkr254] [PMID: 21609964]

[94]
Eichelser C, Stückrath I, Müller V, et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget  2014; 5(20): 9650-63.
 [http://dx.doi.org/10.18632/oncotarget.2520] [PMID: 25333260]

[95]
Mihelich BL, Dambal S, Lin S, Nonn L. miR-182, of the miR-183 cluster family, is packaged in exosomes and is detected in human exosomes from serum, breast cells and prostate cells. Oncol Lett  2016; 12(2): 1197-203.
 [http://dx.doi.org/10.3892/ol.2016.4710] [PMID: 27446418]

[96]
O’Brien K, Lowry MC, Corcoran C, et al. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget  2015; 6(32): 32774-89.
 [http://dx.doi.org/10.18632/oncotarget.5192] [PMID: 26416415]

[97]
De Cola A, Volpe S, Budani MC, et al. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis  2015; 6(7)e1823
 [http://dx.doi.org/10.1038/cddis.2015.192] [PMID: 26181203]
Rights & Permissions Print Cite
Article Metrics
18
3
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1566523223666230215103524	Print ISSN 1566-5232
Publisher Name Bentham Science Publisher	Online ISSN 1875-5631
当代基因治疗

外泌体miRNA作为乳腺癌的下一代治疗载体

摘要

图形摘要

Melatonin Signaling in Health and Disease

The now and future of gene transfer technologies

当代基因治疗

外泌体miRNA作为乳腺癌的下一代治疗载体

摘要

图形摘要

Call for Papers in Thematic Issues

Melatonin Signaling in Health and Disease

The now and future of gene transfer technologies

Related Journals

Related Books

Related Articles
